Suboxone, a medication used to treat opioid use disorder, contains buprenorphine and naloxone. Standard drug screenings do not typically detect buprenorphine unless specifically testing for it. For instance, an individual taking Suboxone will not test positive on a five-panel drug test, which typically screens for substances such as amphetamines, cocaine, opiates, phencyclidine (PCP), and tetrahydrocannabinol (THC).
The ability to specifically detect buprenorphine is crucial for monitoring patient compliance in addiction treatment programs. Its inclusion allows healthcare professionals to ensure patients are adhering to their prescribed medication regimen, contributing to the overall effectiveness of the treatment and reducing the risk of relapse. Historically, the development of specific buprenorphine testing has been instrumental in the evolution of medication-assisted treatment strategies.